Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q2 2019 · 10-Q
Revenue$26.22M$26.22M−35.1% vs Q2 2018 Net Income-$109.87M-$109.87MN/M vs Q2 2018 EPS Diluted-$1.87-$1.87N/M vs Q2 2018 Operating Income-$113,861,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$89,422,000N/M Margins · derivedOperating margin-434.2%−253.7 pt vs Q2 2018
Net margin-419.0%−248.9 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 1, 2019 · 32 d after period end